The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study
Asthma, hay fever and eczema are three common chronic conditions. There are no recent multi-country data on the burden of these three conditions in adults; the aims of this study are to fill this evidence gap.The Global Asthma Network (GAN) Phase I is a multi-country cross-sectional population-based...
Saved in:
| Published in | The European respiratory journal Vol. 60; no. 3; p. 2102865 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
European Respiratory Society
01.09.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Asthma, hay fever and eczema are three common chronic conditions. There are no recent multi-country data on the burden of these three conditions in adults; the aims of this study are to fill this evidence gap.The Global Asthma Network (GAN) Phase I is a multi-country cross-sectional population-based study using the same core methodology as the International Study of Asthma and Allergies in Childhood (ISAAC) Phase III. It provides data on the burden of asthma, hay fever, and eczema not only in children and adolescents but also for the first time in their parents/guardians.Data were available from 193 912 adults (104 061 female; mean age 38 (sd 7.5)) in 43 centres in 17 countries. The overall prevalences (range) of symptoms of current wheeze, asthma ever, hay fever ever and eczema ever were 6.6% (0.9%-32.7%), 4.4%(0.9%-29.0%), 14.4%(2.8%-45.7%), and 9.9%(1.6%-29.5%), respectively. Centre prevalence varied considerably both between countries and within countries. There was a moderate correlation between hay fever ever and asthma ever, and between eczema ever and hay fever ever at the centre level. There were moderate to strong correlations between indicators of the burden of disease reported in adults and the two younger age groups.We found evidence for a substantial burden of asthma, hay fever ever and eczema ever in countries examined highlighting the major public health importance of these diseases. Prevention strategies and equitable access to effective and affordable treatments for these three conditions would help mitigate the avoidable morbidity they cause. |
|---|---|
| AbstractList | AIMSAsthma, hay fever and eczema are three common chronic conditions. There have been no recent multi-country data on the burden of these three conditions in adults; the aims of this study are to fill this evidence gap. METHODSThe Global Asthma Network Phase I is a multi-country cross-sectional population-based study using the same core methodology as the International Study of Asthma and Allergies in Childhood Phase III. It provides data on the burden of asthma, hay fever and eczema in children and adolescents, and, for the first time, in their parents/guardians. RESULTSData were available from 193 912 adults (104 061 female; mean±sd age 38±7.5 years) in 43 centres in 17 countries. The overall prevalence (range) of symptoms was 6.6% (0.9-32.7%) for current wheeze, 4.4% (0.9-29.0%) for asthma ever, 14.4% (2.8-45.7%) for hay fever ever and 9.9% (1.6-29.5%) for eczema ever. Centre prevalence varied considerably both between countries and within countries. There was a moderate correlation between hay fever ever and asthma ever, and between eczema ever and hay fever ever at the centre level. There were moderate to strong correlations between indicators of the burden of disease reported in adults and the two younger age groups. CONCLUSIONWe found evidence for a substantial burden of asthma, hay fever ever and eczema ever in the countries examined, highlighting the major public health importance of these diseases. Prevention strategies and equitable access to effective and affordable treatments for these three conditions would help mitigate the avoidable morbidity they cause. There is a substantial global burden of asthma, hay fever and eczema in adults, which represents a major global public health problem. Accessible, affordable, equitable and effective strategies are needed to reduce this burden across the life-course. https://bit.ly/3uBTQfl Asthma, hay fever and eczema are three common chronic conditions. There are no recent multi-country data on the burden of these three conditions in adults; the aims of this study are to fill this evidence gap.The Global Asthma Network (GAN) Phase I is a multi-country cross-sectional population-based study using the same core methodology as the International Study of Asthma and Allergies in Childhood (ISAAC) Phase III. It provides data on the burden of asthma, hay fever, and eczema not only in children and adolescents but also for the first time in their parents/guardians.Data were available from 193 912 adults (104 061 female; mean age 38 (sd 7.5)) in 43 centres in 17 countries. The overall prevalences (range) of symptoms of current wheeze, asthma ever, hay fever ever and eczema ever were 6.6% (0.9%-32.7%), 4.4%(0.9%-29.0%), 14.4%(2.8%-45.7%), and 9.9%(1.6%-29.5%), respectively. Centre prevalence varied considerably both between countries and within countries. There was a moderate correlation between hay fever ever and asthma ever, and between eczema ever and hay fever ever at the centre level. There were moderate to strong correlations between indicators of the burden of disease reported in adults and the two younger age groups.We found evidence for a substantial burden of asthma, hay fever ever and eczema ever in countries examined highlighting the major public health importance of these diseases. Prevention strategies and equitable access to effective and affordable treatments for these three conditions would help mitigate the avoidable morbidity they cause. Aims Asthma, hay fever and eczema are three common chronic conditions. There have been no recent multi-country data on the burden of these three conditions in adults; the aims of this study are to fill this evidence gap. Methods The Global Asthma Network Phase I is a multi-country cross-sectional population-based study using the same core methodology as the International Study of Asthma and Allergies in Childhood Phase III. It provides data on the burden of asthma, hay fever and eczema in children and adolescents, and, for the first time, in their parents/guardians. Results Data were available from 193 912 adults (104 061 female; mean± sd age 38±7.5 years) in 43 centres in 17 countries. The overall prevalence (range) of symptoms was 6.6% (0.9–32.7%) for current wheeze, 4.4% (0.9–29.0%) for asthma ever, 14.4% (2.8–45.7%) for hay fever ever and 9.9% (1.6–29.5%) for eczema ever. Centre prevalence varied considerably both between countries and within countries. There was a moderate correlation between hay fever ever and asthma ever, and between eczema ever and hay fever ever at the centre level. There were moderate to strong correlations between indicators of the burden of disease reported in adults and the two younger age groups. Conclusion We found evidence for a substantial burden of asthma, hay fever ever and eczema ever in the countries examined, highlighting the major public health importance of these diseases. Prevention strategies and equitable access to effective and affordable treatments for these three conditions would help mitigate the avoidable morbidity they cause. |
| Author | Innes Asher, M Pearce, Neil Ellwood, Eamon El Sony, Asma Marks, Guy B Rutter, Charlotte E Chiang, Chen-Yuan García-Marcos, Luis Silverwood, Richard J Mortimer, Kevin Ellwood, Philippa Strachan, David P Morales, Eva Robertson, Steven Lesosky, Maia Martínez-Torres, Antonela Bissell, Karen Perez-Fernandez, Virginia |
| AuthorAffiliation | 6 ARADyAL Allergy Network, Edificio Departamental-LAIB, Murcia, Spain 7 Dept of Paediatrics: Child and Youth Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand 20 Division of Pulmonary Medicine, Dept of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan 5 Paediatric Allergy and Pulmonology Units, Virgen de la Arrixaca University Children's Hospital, University of Murcia and IMIB Bio-health Research Institute, Murcia, Spain 4 School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa 16 Centre for Longitudinal Studies, UCL Social Research Institute, University College London, London, UK 14 Dept of Public Health Sciences, University of Murcia and IMIB Bio-health Research Institute, Edificio Departamental-LAIB, Murcia, Spain 19 Division of Pulmonary Medicine, Dept of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan 11 Respiratory and Envir |
| AuthorAffiliation_xml | – name: 9 School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand – name: 21 Global Asthma Network Phase I Study Group members are listed at the end of the report – name: 12 Paediatric Allergy and Pulmonology Units and Nurse Research Group, Virgen de la Arrixaca University Children's Hospital, Murcia, Spain – name: 15 Dept of Biostatistics, University of Murcia and IMIB Bio-health Research Institute, Edificio Departamental-LAIB, Murcia, Spain – name: 19 Division of Pulmonary Medicine, Dept of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan – name: 13 IMIB Bio-health Research Institute, Edificio Departamental-LAIB, Murcia, Spain – name: 1 Dept of Medicine, University of Cambridge, Cambridge, UK – name: 11 Respiratory and Environmental Epidemiology, University of New South Wales, Sydney, Australia – name: 2 Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK – name: 8 Dept of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK – name: 6 ARADyAL Allergy Network, Edificio Departamental-LAIB, Murcia, Spain – name: 4 School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa – name: 5 Paediatric Allergy and Pulmonology Units, Virgen de la Arrixaca University Children's Hospital, University of Murcia and IMIB Bio-health Research Institute, Murcia, Spain – name: 10 Epidemiological Laboratory (Epi-Lab) for Public Health, Research and Development, Khartoum, Sudan – name: 3 Dept of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK – name: 18 International Union Against Tuberculosis and Lung Disease, Paris, France – name: 20 Division of Pulmonary Medicine, Dept of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan – name: 17 Population Health Research Institute, St George's, University of London, London, UK – name: 14 Dept of Public Health Sciences, University of Murcia and IMIB Bio-health Research Institute, Edificio Departamental-LAIB, Murcia, Spain – name: 7 Dept of Paediatrics: Child and Youth Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand – name: 16 Centre for Longitudinal Studies, UCL Social Research Institute, University College London, London, UK |
| Author_xml | – sequence: 1 givenname: Kevin surname: Mortimer fullname: Mortimer, Kevin organization: Full professor – sequence: 2 givenname: Maia surname: Lesosky fullname: Lesosky, Maia organization: Full professor – sequence: 3 givenname: Luis orcidid: 0000-0002-0925-3851 surname: García-Marcos fullname: García-Marcos, Luis organization: Full professor – sequence: 4 givenname: M orcidid: 0000-0003-1768-3832 surname: Innes Asher fullname: Innes Asher, M organization: Full professor – sequence: 5 givenname: Neil surname: Pearce fullname: Pearce, Neil organization: Full professor – sequence: 6 givenname: Eamon orcidid: 0000-0003-2626-6619 surname: Ellwood fullname: Ellwood, Eamon organization: Department of Paediatrics: Child and Youth Health, Faculty of Medical and Health Sciences, University of Auckland, , Auckland, New Zealand – sequence: 7 givenname: Karen surname: Bissell fullname: Bissell, Karen organization: School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand – sequence: 8 givenname: Asma orcidid: 0000-0002-6989-8862 surname: El Sony fullname: El Sony, Asma organization: Full professor – sequence: 9 givenname: Philippa orcidid: 0000-0002-1994-4023 surname: Ellwood fullname: Ellwood, Philippa organization: Department of Paediatrics: Child and Youth Health, Faculty of Medical and Health Sciences, University of Auckland, , Auckland, New Zealand – sequence: 10 givenname: Guy B orcidid: 0000-0002-8976-8053 surname: Marks fullname: Marks, Guy B organization: Full professor – sequence: 11 givenname: Antonela surname: Martínez-Torres fullname: Martínez-Torres, Antonela organization: IMIB Bio-health Research Institute, Murcia, Edificio Departamental-Laib, Murcia, Spain – sequence: 12 givenname: Eva surname: Morales fullname: Morales, Eva organization: Department of Public Health Sciences, University of Murcia, and IMIB Bio-health Research Institute, Edificio Departamental-Laib, Murcia, Spain – sequence: 13 givenname: Virginia orcidid: 0000-0003-1877-3055 surname: Perez-Fernandez fullname: Perez-Fernandez, Virginia organization: Full professor – sequence: 14 givenname: Steven surname: Robertson fullname: Robertson, Steven organization: Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK – sequence: 15 givenname: Charlotte E surname: Rutter fullname: Rutter, Charlotte E organization: Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK – sequence: 16 givenname: Richard J orcidid: 0000-0002-2744-1194 surname: Silverwood fullname: Silverwood, Richard J organization: Centre for Longitudinal Studies, UCL Social Research Institute, University College London, , London WC1H 0AL, UK – sequence: 17 givenname: David P surname: Strachan fullname: Strachan, David P organization: Full professor – sequence: 18 givenname: Chen-Yuan orcidid: 0000-0002-9291-2490 surname: Chiang fullname: Chiang, Chen-Yuan email: cychiang@tmu.edu.tw organization: Global Asthma Network Phase I Study Group listed at the end of the report |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35210319$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkUtP3TAQhS0EggvtL6hUedlFQ22P48QsKiFUHhICFlRdWhN73KTKA-IE6fLrueEluprRmTlnRvr22XY_9MTYFykOpSzhhwRrQQg4FKo0eaaEkltstajZIm-zlbACMmnB7LH9lP4JIY0Gucv2IFdSgLQr9ue2Jl7NY6CeD5FjmuoOv_Ma1zzSA40c-8DJP1KHvOk5hrmd0tLJgvth7qexoXTEz46v-E2NifgFT9Mc1p_YTsQ20efXesB-n_66PTnPLq_PLk6OLzOvRT5lVa5tHiNENEETWSyBrMS8lAakkUWJ3ktVhAoUlNFYVVEUqIWoch-UDXDAfr7k3s1VR8HT5iNs3d3YdDiu3YCN-3_SN7X7Ozw4qwtdWr0J-PYaMA73M6XJdU3y1LbY0zAnpwxAWWhTqM0qvKz6cUhppPh-Rgq3IHFvSNwzErcg2bi-fvzw3fPGAJ4ArOGHyQ |
| CitedBy_id | crossref_primary_10_2147_CCID_S405491 crossref_primary_10_3390_ijms25052903 crossref_primary_10_1080_09603123_2024_2352597 crossref_primary_10_1136_bmjopen_2022_070784 crossref_primary_10_1186_s12931_024_02811_4 crossref_primary_10_29392_001c_56661 crossref_primary_10_1111_resp_14774 crossref_primary_10_1016_S0140_6736_22_02125_0 crossref_primary_10_1111_jdv_19958 crossref_primary_10_1136_thorax_2023_220603 crossref_primary_10_1056_EVIDpp2300292 crossref_primary_10_1007_s10753_023_01892_5 crossref_primary_10_3390_jcm12196335 crossref_primary_10_3390_children11060657 crossref_primary_10_4103_sujhs_sujhs_30_23 crossref_primary_10_1111_cea_14266 crossref_primary_10_3389_fpsyg_2023_1221648 crossref_primary_10_3389_fcell_2023_1241008 crossref_primary_10_3390_biomedicines10102635 crossref_primary_10_3389_fimmu_2024_1375340 crossref_primary_10_1002_cpt_3254 crossref_primary_10_1007_s43465_023_01048_5 crossref_primary_10_1093_annweh_wxad044 crossref_primary_10_2147_JAA_S437944 crossref_primary_10_1016_j_jad_2022_07_013 crossref_primary_10_2147_JAA_S423884 crossref_primary_10_3390_ijms24054804 crossref_primary_10_1186_s12864_023_09400_7 crossref_primary_10_1016_S2214_109X_22_00506_X crossref_primary_10_1136_bmjresp_2023_001895 crossref_primary_10_1183_13993003_00440_2022 crossref_primary_10_3390_ijms25137395 crossref_primary_10_25259_JPATS_37_2022 crossref_primary_10_35366_111084 crossref_primary_10_1016_j_waojou_2023_100794 crossref_primary_10_1007_s11739_024_03648_x crossref_primary_10_1183_13993003_03179_2021 crossref_primary_10_1016_j_jaip_2024_03_043 crossref_primary_10_3390_ijms25020730 crossref_primary_10_25259_JPATS_12_2022 |
| Cites_doi | 10.1093/ije/dyh031 10.1136/oem.2002.006809 10.1016/S0140-6736(21)00458-X 10.1111/j.1398-9995.2007.01524.x 10.1016/S0140-6736(06)69283-0 10.1183/09031936.94.07050954 10.1183/09031936.98.12020315 10.1016/j.anai.2017.10.037 10.1016/S2213-2600(18)30513-7 10.3390/jcm9113688 10.1111/j.1365-2222.2003.01816.x 10.1183/09031936.01.00205801 10.1016/S0091-6749(99)70536-1 10.1016/S0140-6736(97)07302-9 10.1183/13993003.02866-2021 10.1016/S0140-6736(20)30925-9 10.1136/thx.2006.070169 10.1183/09031936.00027509 10.1183/13993003.03179-2021 10.1183/13993003.01605-2016 10.1111/bjd.12196 10.1016/j.jaci.2009.10.009 10.1183/09031936.02.00046802 10.1183/09031936.96.09040687 10.1136/thx.2008.106609 10.1016/S0140-6736(21)01450-1 10.1183/09031936.01.17304360 10.1111/j.1399-3038.1997.tb00156.x 10.5588/ijtld.22.0034 |
| ContentType | Journal Article |
| Copyright | Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org. Copyright ©The authors 2022. 2022 |
| Copyright_xml | – notice: Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org. – notice: Copyright ©The authors 2022. 2022 |
| CorporateAuthor | Global Asthma Network Phase I Study Group |
| CorporateAuthor_xml | – name: Global Asthma Network Phase I Study Group |
| DBID | NPM AAYXX CITATION 7X8 5PM |
| DOI | 10.1183/13993003.02865-2021 |
| DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Burden of asthma, hay fever and eczema in adults |
| EISSN | 1399-3003 |
| ExternalDocumentID | 10_1183_13993003_02865_2021 35210319 |
| Genre | Journal Article |
| GroupedDBID | --- .55 18M 1OC 2WC 53G 5GY 5RE 5VS AADJU AAFWJ ABCQX ABOCM ABSQV ACEMG ACGFO ACPRK ADBBV ADDZX AENEX AFHIN AIZTS ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CS3 DIK E3Z EBS EJD F5P F9R GX1 H13 INIJC KQ8 L7B NPM OK1 P2P PQQKQ R0Z RHF RHI TER TR2 W8F WOQ X7M ~02 .GJ 31~ 3O- 8-1 AAYXX ACXQS AFFNX AFZJQ AJAOE CAG CITATION COF J5H LH4 LW6 ZE2 ZGI ZXP 7X8 5PM |
| ID | FETCH-LOGICAL-c405t-b5495ff3fa6d4ee9a83e91a5816316178acc127db3238f692bef0a400b5cd29d3 |
| ISSN | 0903-1936 |
| IngestDate | Tue Sep 17 21:36:20 EDT 2024 Fri Oct 25 07:32:05 EDT 2024 Wed Oct 23 14:21:38 EDT 2024 Sat Sep 28 08:21:26 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c405t-b5495ff3fa6d4ee9a83e91a5816316178acc127db3238f692bef0a400b5cd29d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-9291-2490 0000-0002-8976-8053 0000-0003-1877-3055 0000-0003-1768-3832 0000-0003-2626-6619 0000-0002-1994-4023 0000-0002-6989-8862 0000-0002-2744-1194 0000-0002-0925-3851 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC9474894 |
| PMID | 35210319 |
| PQID | 2633874672 |
| PQPubID | 23479 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9474894 proquest_miscellaneous_2633874672 crossref_primary_10_1183_13993003_02865_2021 pubmed_primary_35210319 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-09-01 |
| PublicationDateYYYYMMDD | 2022-09-01 |
| PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | The European respiratory journal |
| PublicationTitleAlternate | Eur Respir J |
| PublicationYear | 2022 |
| Publisher | European Respiratory Society |
| Publisher_xml | – name: European Respiratory Society |
| References | 2024102102531544000_60.3.2102865.8 2024102102531544000_60.3.2102865.9 2024102102531544000_60.3.2102865.6 Ellwood (2024102102531544000_60.3.2102865.22) 2020; 9 Asher (2024102102531544000_60.3.2102865.4) 2019; 7 2024102102531544000_60.3.2102865.14 2024102102531544000_60.3.2102865.13 2024102102531544000_60.3.2102865.15 2024102102531544000_60.3.2102865.18 2024102102531544000_60.3.2102865.19 2024102102531544000_60.3.2102865.30 2024102102531544000_60.3.2102865.10 Hill (2024102102531544000_60.3.2102865.32) 2018; 120 2024102102531544000_60.3.2102865.31 2024102102531544000_60.3.2102865.12 Meghji (2024102102531544000_60.3.2102865.1) 2021; 397 2024102102531544000_60.3.2102865.11 Ellwood (2024102102531544000_60.3.2102865.16) 2009; 13 2024102102531544000_60.3.2102865.25 2024102102531544000_60.3.2102865.24 2024102102531544000_60.3.2102865.27 2024102102531544000_60.3.2102865.26 Ellwood (2024102102531544000_60.3.2102865.17) 2017; 49 2024102102531544000_60.3.2102865.29 2024102102531544000_60.3.2102865.28 Strachan (2024102102531544000_60.3.2102865.7) 1997; 8 2024102102531544000_60.3.2102865.21 2024102102531544000_60.3.2102865.5 2024102102531544000_60.3.2102865.20 2024102102531544000_60.3.2102865.2 2024102102531544000_60.3.2102865.23 2024102102531544000_60.3.2102865.3 |
| References_xml | – ident: 2024102102531544000_60.3.2102865.10 doi: 10.1093/ije/dyh031 – ident: 2024102102531544000_60.3.2102865.11 doi: 10.1136/oem.2002.006809 – volume: 397 start-page: 928 year: 2021 ident: 2024102102531544000_60.3.2102865.1 article-title: Improving lung health in low-income and middle-income countries: from challenges to solutions publication-title: Lancet doi: 10.1016/S0140-6736(21)00458-X contributor: fullname: Meghji – ident: 2024102102531544000_60.3.2102865.29 doi: 10.1111/j.1398-9995.2007.01524.x – ident: 2024102102531544000_60.3.2102865.13 doi: 10.1016/S0140-6736(06)69283-0 – ident: 2024102102531544000_60.3.2102865.25 doi: 10.1183/09031936.94.07050954 – ident: 2024102102531544000_60.3.2102865.6 doi: 10.1183/09031936.98.12020315 – volume: 120 start-page: 131 year: 2018 ident: 2024102102531544000_60.3.2102865.32 article-title: The atopic march: Critical evidence and clinical relevance publication-title: Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2017.10.037 contributor: fullname: Hill – volume: 7 start-page: 13 year: 2019 ident: 2024102102531544000_60.3.2102865.4 article-title: Calling time on asthma deaths in tropical regions: how much longer must people wait for essential medicines? publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(18)30513-7 contributor: fullname: Asher – volume: 9 start-page: 3688 year: 2020 ident: 2024102102531544000_60.3.2102865.22 article-title: Global Asthma Network Phase I surveillance: geographical coverage and response rates publication-title: J Clin Med doi: 10.3390/jcm9113688 contributor: fullname: Ellwood – ident: 2024102102531544000_60.3.2102865.12 doi: 10.1111/j.1365-2222.2003.01816.x – ident: 2024102102531544000_60.3.2102865.27 doi: 10.1183/09031936.01.00205801 – ident: 2024102102531544000_60.3.2102865.8 doi: 10.1016/S0091-6749(99)70536-1 – ident: 2024102102531544000_60.3.2102865.5 doi: 10.1016/S0140-6736(97)07302-9 – ident: 2024102102531544000_60.3.2102865.19 doi: 10.1183/13993003.02866-2021 – ident: 2024102102531544000_60.3.2102865.2 doi: 10.1016/S0140-6736(20)30925-9 – ident: 2024102102531544000_60.3.2102865.14 doi: 10.1136/thx.2006.070169 – ident: 2024102102531544000_60.3.2102865.18 doi: 10.1183/09031936.00027509 – ident: 2024102102531544000_60.3.2102865.3 doi: 10.1183/13993003.03179-2021 – volume: 49 start-page: 1601605 year: 2017 ident: 2024102102531544000_60.3.2102865.17 article-title: The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors publication-title: Eur Respir J doi: 10.1183/13993003.01605-2016 contributor: fullname: Ellwood – ident: 2024102102531544000_60.3.2102865.21 – ident: 2024102102531544000_60.3.2102865.31 doi: 10.1111/bjd.12196 – volume: 13 start-page: 1174 year: 2009 ident: 2024102102531544000_60.3.2102865.16 article-title: Translation of questions: the International Study of Asthma and Allergies in Childhood (ISAAC) experience publication-title: Int J Tuberc Lung Dis contributor: fullname: Ellwood – ident: 2024102102531544000_60.3.2102865.24 – ident: 2024102102531544000_60.3.2102865.30 doi: 10.1016/j.jaci.2009.10.009 – ident: 2024102102531544000_60.3.2102865.20 doi: 10.1183/09031936.02.00046802 – ident: 2024102102531544000_60.3.2102865.26 doi: 10.1183/09031936.96.09040687 – ident: 2024102102531544000_60.3.2102865.15 doi: 10.1136/thx.2008.106609 – ident: 2024102102531544000_60.3.2102865.23 doi: 10.1016/S0140-6736(21)01450-1 – ident: 2024102102531544000_60.3.2102865.9 doi: 10.1183/09031936.01.17304360 – volume: 8 start-page: 161 year: 1997 ident: 2024102102531544000_60.3.2102865.7 article-title: Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC) publication-title: Pediatr Allergy Immunol doi: 10.1111/j.1399-3038.1997.tb00156.x contributor: fullname: Strachan – ident: 2024102102531544000_60.3.2102865.28 doi: 10.5588/ijtld.22.0034 |
| SSID | ssj0016431 |
| Score | 2.625716 |
| Snippet | Asthma, hay fever and eczema are three common chronic conditions. There are no recent multi-country data on the burden of these three conditions in adults; the... Aims Asthma, hay fever and eczema are three common chronic conditions. There have been no recent multi-country data on the burden of these three conditions in... AIMSAsthma, hay fever and eczema are three common chronic conditions. There have been no recent multi-country data on the burden of these three conditions in... There is a substantial global burden of asthma, hay fever and eczema in adults, which represents a major global public health problem. Accessible, affordable,... |
| SourceID | pubmedcentral proquest crossref pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | 2102865 |
| SubjectTerms | Original s |
| Title | The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35210319 https://search.proquest.com/docview/2633874672 https://pubmed.ncbi.nlm.nih.gov/PMC9474894 |
| Volume | 60 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgkRAXxJvykpG4dbM075hbBfti2wJSK3qLnNhWg7Qp2qYH9tfz2c6r0MPCJbLSxmlnPs_DM54h5J2MFYs5x0IaZdIJhBc4LNGOq8cTpSIRSWGyfGfR2SL4vAyXXbsjc7qkyo7y673nSv6Hq7gHvupTsv_A2XZS3MAY_MUVHMb1xjzOzDkEE87fVKtLYwuu-K-hkvg7JjQg82t5yfXGhim2YRJg3XhoukRoR1lvCpyOZ8OvK2i04Xmv4uyP7jXtrv1VLzbf_5F14m5Rd2O5gMLtZfts1vUm7ZQXrSI4xSIzgfpP3JlibDP-JtuitfPHTV_2KQRZKXf2KODeNklYUDFWrsIOcvzRyO8LXttIoAaYv1-eJ7quhH5aP3w00udoAQHP7dRXE7KffUlPFpNJOj9ezm-TOx4Ej5Z4F9-6qBKsL7euPIWJ3--Zdtc6-cvl-DNztmeKzB-Q-7UPQccWEA_JLVk-InendZbEY_IdDKMWF3StqMXFIQUqqEEFBSqoRQUtSmpRoUduTFtUfKDABDWYoOfUYOIJWZwczz-eOXUDDSeHHV45GZz_UClf8UgEUjKe-JK5PExghGu_NuF57nqxyHwYbipiXibViEOqZ2EuPCb8p-SgXJfyOaEi4oGLdRsKroI8YwyKMnYzN85ZIiC5B-SwIVz609ZJSY1_mfhpQ-fU0DnVdB6Qtw1xU8gzHaTipVxvN6kX-ZgZ6tsbkGeW2O2EcBZ0VxI2IPEOG9ov6Frpu5-UxcrUTGeBLrMUvLjBe1-Sex2GX5GD6morX8PyrLI3Bk6_ATvWgmo |
| link.rule.ids | 230,315,783,787,888,27936,27937 |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+burden+of+asthma%2C+hay+fever+and+eczema+in+adults+in+17+countries%3A+GAN+Phase+I+study&rft.jtitle=The+European+respiratory+journal&rft.au=Mortimer%2C+Kevin&rft.au=Lesosky%2C+Maia&rft.au=Garc%C3%ADa-Marcos%2C+Luis&rft.au=Asher%2C+M+Innes&rft.date=2022-09-01&rft.eissn=1399-3003&rft.volume=60&rft.issue=3&rft_id=info:doi/10.1183%2F13993003.02865-2021&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0903-1936&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0903-1936&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0903-1936&client=summon |